Anifrolumab Real-world Treatment Outcomes in Polish Patients With Systemic Lupus Erythematosus (SLE). Multicenter, Non-interventional Study
Status: Recruiting
Location: See all (11) locations...
Intervention Type: Drug
Study Type: Observational
SUMMARY
The Polish multicentre observational (non-interventional) study aiming to collect data on the characteristic of patients with systemic lupus erythematosus and clinical outcomes of anifrolumab administered in the scope of routine clinical practice.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Adult (aged ≥18 years old) patients with SLE who received anifrolumab treatment in the frames of NDP in Poland.
• Patients willing to participate in the study and signed Informed Consent Form (ICF).
Locations
Other Locations
Poland
Research Site
RECRUITING
Bydgoszcz
Research Site
RECRUITING
Bytom
Research Site
RECRUITING
Gdansk
Research Site
RECRUITING
Katowice
Research Site
RECRUITING
Krakow
Research Site
RECRUITING
Lodz
Research Site
RECRUITING
Lublin
Research Site
RECRUITING
Poznan
Research Site
RECRUITING
Rzeszów
Research Site
RECRUITING
Warsaw
Research Site
RECRUITING
Wroclaw
Contact Information
Primary
AstraZeneca Clinical Study Information Center
information.center@astrazeneca.com
1-877-240-9479
Time Frame
Start Date: 2025-02-28
Estimated Completion Date: 2028-06-30
Participants
Target number of participants: 100
Treatments
SLE Patients
Open-lable arm with SLE patients who received anifrolumab treatment in the frames of NDP in Poland.
Related Therapeutic Areas
Sponsors
Leads: AstraZeneca